Abstract
Purpose Genetic penetrance is the probability of a phenotype manifesting if one harbours a specific pathogenic variant. For most Mendelian genes, penetrance is incomplete and may be age-dependent. Accurate penetrance estimates are important in many biomedical fields including genetic counselling, disease research, and for gene therapy. The main methods for its estimation are limited in situations where large family pedigrees are not available, the disease is rare, late onset, or complex.
Methods Here we present a novel method for penetrance estimation in autosomal dominant phenotypes. It uses population-scale data regarding the distribution of a variant among unrelated people affected (cases) and unaffected (controls) by an associated phenotype and can be operated using samples of affected people only by considering family disease history.
Results The method is validated within simulation studies. Candidate variant-disease case studies yield estimates which align with existing disease knowledge and estimates derived using established methods.
Conclusion We have presented a valid method for penetrance estimation in autosomal dominant traits which avoids kinship-specific penetrance estimates and the ascertainment biases that can arise when sampling rare variants among control populations. It can be accessed from our public web server (https://adpenetrance.rosalind.kcl.ac.uk) and is available as an open-source R library (https://github.com/ThomasPSpargo/adpenetrance).
Competing Interest Statement
CML sits on the SAB for Myriad Neuroscience. AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen Idec, Brainstorm, Cytokinetics, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, and Wave Pharmaceuticals
Funding Statement
This is an EU Joint Programme-Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND- http://www.neurodegenerationresearch.eu/ (United Kingdom, Medical Research Council MR/L501529/1 to A.A.-C., principal investigator [PI] and MR/R024804/1 to A.A.-C., PI]; Economic and Social Research Council ES/L008238/1 to A.A.-C. [co-PI]) and through the Motor Neurone Disease Association. This study represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The work leading up to this publication was funded by the European Community's Horizon 2020 Programme (H2020-PHC-2014-two-stage; grant 633413). We acknowledge use of the research computing facility at King's College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guy's & St. Thomas' NHS Foundation Trusts and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guy's and St Thomas' Charity (TR130505). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, King's College London, or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work involved analysis of already published data only and as such IRB approval was not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* co-senior author
Updated penetrance estimation approach; additional steps taken to validate approach (presented in Supplementary Methods); reanalysis of all case studies with revised method; additional analyses for sub-populations included within Case Study 1 (Table S2); revised discussion to address further considerations relevant to the method and penetrance estimates made.
Data Availability
All data referred to in the manuscript is publicly available the original sources are referenced within. An R library containing the relevant scripts for our method, including validation and analysis of case studies, is hosted on GitHub: https://github.com/ThomasPSpargo/adpenetrance
